GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (LSE:4BB) » Definitions » Short-Term Debt

4basebio (LSE:4BB) Short-Term Debt : £0.00 Mil (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is 4basebio Short-Term Debt?

4basebio's Short-Term Debt for the quarter that ended in Jun. 2023 was £0.00 Mil.

4basebio's quarterly Short-Term Debt increased from Jun. 2022 (£0.00 Mil) to Dec. 2022 (£0.32 Mil) but then declined from Dec. 2022 (£0.32 Mil) to Jun. 2023 (£0.00 Mil).

4basebio's annual Short-Term Debt increased from Dec. 2020 (£0.35 Mil) to Dec. 2021 (£0.36 Mil) but then declined from Dec. 2021 (£0.36 Mil) to Dec. 2022 (£0.32 Mil).


4basebio Short-Term Debt Historical Data

The historical data trend for 4basebio's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4basebio Short-Term Debt Chart

4basebio Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Short-Term Debt
0.40 0.35 0.36 0.32

4basebio Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Short-Term Debt Get a 7-Day Free Trial - 0.36 - 0.32 -

4basebio Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


4basebio Short-Term Debt Related Terms

Thank you for viewing the detailed overview of 4basebio's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


4basebio (LSE:4BB) Business Description

Traded in Other Exchanges
Address
25 Norman Way, Over, Cambridge, GBR, CB24 5QE
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.

4basebio (LSE:4BB) Headlines

No Headlines